Breaking News Instant updates and real-time market news.

DBVT

DBV Technologies

$48.07

0.92 (1.95%)

17:21
10/20/17
10/20
17:21
10/20/17
17:21

DBV Technologies: PEPITES trial does not reach primary endpoint

DBV Technologies announced topline results from the PEPITES, or Peanut EPIT Efficacy and Safety, Phase III trial evaluating the safety and efficacy of Viaskin Peanut in children four to 11 years of age. Topline results show a statistically significant response with a favorable tolerability profile, with 35.3% of patients responding to Viaskin Peanut 250 microg after 12 months of treatment as compared to 13.6% of patients in the placebo arm. However, the primary endpoint, which evaluates the 95% confidence interval in the difference in response rates between the active and placebo arms, did not reach the 15% lower bound of the CI that was proposed in the study's Statistical Analysis Plan submitted to the U.S Food and Drug Administration. Following initial conversations with the FDA on these topline efficacy and safety results, DBV will continue ongoing discussions with the agency, and plans to proceed with the BLA preparation process. "We believe that this preliminary analysis shows significant therapeutic promise in the peanut-allergic population, where there is a high unmet medical need and no approved treatments," said Dr. Pierre-Henri Benhamou, Chairman & Chief Executive Officer of DBV Technologies. "Viaskin Peanut has been granted both Breakthrough Therapy and Fast Track designations by the FDA for the treatment of peanut allergy. We are committed to working together with the regulatory agencies to bring forward a safe and effective treatment option for these patients."

DBVT DBV Technologies
$48.07

0.92 (1.95%)

10/02/17
JMPS
10/02/17
NO CHANGE
JMPS
Outperform
Parents excited about peanut allergy immunotherapy, says JMP Securities
After surveying over 60 parents with peanut allergic children, JMP Securities analyst Liisa Bayko said she was "surprised" that 85% of respondents indicated a willingness to adopt an immunotherapy to treat the allergy. While the survey group may represent a more engaged and proactive one than the larger population, Bayko said even 30% adoption would be significant as the peanut allergy market is "enormous". The analyst, who added the survey pointed to a place for both oral and epicutaneous approaches, keeps Outperform ratings on both DBV Technologies (DBVT) and Aimmune (AIMT).
10/06/17
DBAB
10/06/17
NO CHANGE
Target $56
DBAB
Buy
DBV risk/reward favorable into Phase 3 readout, says Deutsche Bank
Deutsche Bank analyst Andrew Peters says the risk/reward for DBV Technologies, despite the stock rallying 31% year-to-date, is favorable into the Phase 3 data readout for Viaskin Peanut expected this month. The analyst continues to see a "strong rationale" for why the study should be successful. The current share value may still underappreciate the potential upside on positive data, Peters tells investors in a research note. He reiterates a Buy rating on DBV with a $56 price target.
10/12/17
SBSH
10/12/17
NO CHANGE
Target $57
SBSH
Buy
DBV news today does not impact timelines for efficacy study, says Citi
Citi analyst Liav Abraham says she confirmed with management of DBV Technologies that today's announcement regarding the Realise study has no bearing on the timelines for readout of the pivotal efficacy study for Viaksin Peanut, the Pepites study, which remains on track for a headline data readout this month. The analyst remains "constructive" on the shares ahead of the Pepites data readout in October. She notes that Realise is DBV's second Phase III study for Viaskin Peanut, and is a safety study, unlike Pepites, which is an efficacy study. Abraham has a Buy rating on DBV with a $57 price target.
10/20/17
PIPR
10/20/17
NO CHANGE
Target $38
PIPR
Overweight
Piper sees ' increasingly favorable' risk/reward for Aimmune Phase III program
After hosting investor meetings with management, Piper Jaffray analyst Charles Duncan sees an "increasingly favorable" risk/reward for Aimmune Therapeutics' (AIMT) AR101 Phase III peanut allergy program heading into the clinical progress results in Q1 of 2018. Aimmune has a "best-in-class" approach to peanut allergy immunotherapy which can address at least 25%-40%) of the moderate to severe peanut allergic market, Duncan tells investors in a research note. The analyst believes some volatility in the shares is possible around the near-term Phase III Pepites results from "mind-share competitor" DBV Technologies (DBVT). Duncan views Aimmune as undervalued and keeps an Overweight rating on the shares with a $38 price target.

TODAY'S FREE FLY STORIES

PDFS

PDF Solutions

$15.86

0.11 (0.70%)

, BBOX

Black Box

$4.15

0.55 (15.28%)

17:59
11/21/17
11/21
17:59
11/21/17
17:59
Hot Stocks
Breaking Hot Stocks news story on PDF Solutions, Black Box »

PDF Solutions to replace…

PDFS

PDF Solutions

$15.86

0.11 (0.70%)

BBOX

Black Box

$4.15

0.55 (15.28%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HPQ

HP Inc.

$22.46

0.34 (1.54%)

17:58
11/21/17
11/21
17:58
11/21/17
17:58
Hot Stocks
Breaking Hot Stocks news story on HP Inc. »

HP Inc. sees pressure on…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Nov

CEIX

CONSOL Energy

, ICON

Iconix Brand

$2.55

0.28 (12.33%)

17:57
11/21/17
11/21
17:57
11/21/17
17:57
Hot Stocks
Breaking Hot Stocks news story on CONSOL Energy, Iconix Brand »

CONSOL Energy to replace…

CEIX

CONSOL Energy

ICON

Iconix Brand

$2.55

0.28 (12.33%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HPQ

HP Inc.

$22.46

0.34 (1.54%)

17:53
11/21/17
11/21
17:53
11/21/17
17:53
Hot Stocks
Breaking Hot Stocks news story on HP Inc. »

HP Inc. says returned…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Nov

TMQ

Trilogy Metals

$0.92

-0.0211 (-2.25%)

17:53
11/21/17
11/21
17:53
11/21/17
17:53
Syndicate
Breaking Syndicate news story on Trilogy Metals »

Trilogy Metals files to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TRNO

Terreno Realty

$37.74

0.74 (2.00%)

17:50
11/21/17
11/21
17:50
11/21/17
17:50
Initiation
Terreno Realty initiated  »

Terreno Realty initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Dec

HPQ

HP Inc.

$22.47

0.355 (1.61%)

17:47
11/21/17
11/21
17:47
11/21/17
17:47
Hot Stocks
HP Inc.: 'Stay tuned' for news on metal 3D printing »

Says plans to introduce…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Nov

THC

Tenet

$13.34

0.17 (1.29%)

17:47
11/21/17
11/21
17:47
11/21/17
17:47
Initiation
Tenet initiated  »

Tenet initiated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LPNT

LifePoint

$43.85

0.65 (1.50%)

17:47
11/21/17
11/21
17:47
11/21/17
17:47
Initiation
LifePoint initiated  »

LifePoint initiated with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LHCG

LHC Group

$67.98

1.46 (2.19%)

17:46
11/21/17
11/21
17:46
11/21/17
17:46
Initiation
LHC Group initiated  »

LHC Group initiated with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Dec

  • 13

    Dec

HLS

HealthSouth

$48.46

0.85 (1.79%)

17:46
11/21/17
11/21
17:46
11/21/17
17:46
Initiation
HealthSouth initiated  »

HealthSouth initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HCA

HCA Healthcare

$75.89

1.28 (1.72%)

17:46
11/21/17
11/21
17:46
11/21/17
17:46
Initiation
HCA Healthcare initiated  »

HCA Healthcare initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Dec

AMED

Amedisys

$54.97

2.29 (4.35%)

17:45
11/21/17
11/21
17:45
11/21/17
17:45
Initiation
Amedisys initiated  »

Amedisys initiated with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HPQ

HP Inc.

$22.46

0.34 (1.54%)

17:45
11/21/17
11/21
17:45
11/21/17
17:45
Hot Stocks
HP Inc. sees printing segment continuing to make 'significant' progress »

Comments taken from Q4…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Nov

17:45
11/21/17
11/21
17:45
11/21/17
17:45
General news
Breaking General news story  »

Federal Reserve Chair…

AXTA

Axalta Coating

$33.87

0.33 (0.98%)

, AKZOY

AkzoNobel

$30.57

0.085 (0.28%)

17:38
11/21/17
11/21
17:38
11/21/17
17:38
Periodicals
Nippon made all-cash offer to buy Axalta Coating, Reuters reports »

Japan's Nippon Paint…

AXTA

Axalta Coating

$33.87

0.33 (0.98%)

AKZOY

AkzoNobel

$30.57

0.085 (0.28%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TIVO

TiVo

$17.65

0.15 (0.86%)

, CMCSA

Comcast

$36.42

0.59 (1.65%)

17:34
11/21/17
11/21
17:34
11/21/17
17:34
Hot Stocks
TiVo wins ITC patent lawsuit against Comcast »

TiVo (TIVO) has won its…

TIVO

TiVo

$17.65

0.15 (0.86%)

CMCSA

Comcast

$36.42

0.59 (1.65%)

CMCSK

Comcast

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GME

GameStop

$16.73

0.29 (1.76%)

, AXTA

Axalta Coating

$33.87

0.33 (0.98%)

17:27
11/21/17
11/21
17:27
11/21/17
17:27
Hot Stocks
On The Fly: After Hours Movers »

UP AFTER EARNINGS:…

GME

GameStop

$16.73

0.29 (1.76%)

AXTA

Axalta Coating

$33.87

0.33 (0.98%)

AKZOY

AkzoNobel

$30.57

0.085 (0.28%)

EXEL

Exelixis

$26.05

0.4 (1.56%)

GES

Guess

$17.95

0.17 (0.96%)

CAL

Caleres

$30.99

0.05 (0.16%)

HPQ

HP Inc.

$22.46

0.34 (1.54%)

CRM

Salesforce

$108.80

1.43 (1.33%)

HPE

HP Enterprise

$14.12

0.03 (0.21%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Nov

  • 21

    Nov

  • 21

    Nov

  • 21

    Nov

  • 21

    Nov

  • 21

    Nov

  • 27

    Nov

  • 28

    Nov

  • 11

    Dec

SSY

SunLink Health Systems

$1.52

0.03 (2.01%)

17:27
11/21/17
11/21
17:27
11/21/17
17:27
Hot Stocks
SunLink Health Systems commences tender offer to repurchase 1.56M shares »

SunLink Health Systems…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TYHT

Shineco

$3.26

-0.27 (-7.65%)

17:26
11/21/17
11/21
17:26
11/21/17
17:26
Syndicate
Breaking Syndicate news story on Shineco »

Shineco files $25M mixed…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RMNI

Rimini Street

$7.54

0.0842 (1.13%)

17:22
11/21/17
11/21
17:22
11/21/17
17:22
Syndicate
Rimini Street files to sell 22.11M shares of common stock for holders »

Also files to sell 6.06M…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CRM

Salesforce

$108.80

1.43 (1.33%)

17:20
11/21/17
11/21
17:20
11/21/17
17:20
Earnings
Breaking Earnings news story on Salesforce »

Salesforce says sees Q4…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Nov

  • 27

    Nov

GME

GameStop

$16.74

0.31 (1.89%)

17:18
11/21/17
11/21
17:18
11/21/17
17:18
Hot Stocks
GameStop 'on track' to achieve FY17 collectibles revenue view »

Says "on track"…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Nov

GME

GameStop

$16.73

0.29 (1.76%)

, NTDOY

Nintendo

$49.83

-0.228 (-0.46%)

17:16
11/21/17
11/21
17:16
11/21/17
17:16
Hot Stocks
GameStop: Xbox One X has already had 'strong start' »

GameStop (GME) says it…

GME

GameStop

$16.73

0.29 (1.76%)

NTDOY

Nintendo

$49.83

-0.228 (-0.46%)

MSFT

Microsoft

$83.72

1.19 (1.44%)

ATVI

Activision Blizzard

$64.50

0.57 (0.89%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Nov

CRM

Salesforce

$108.80

1.43 (1.33%)

, AMZN

Amazon.com

$1,139.49

13.18 (1.17%)

17:14
11/21/17
11/21
17:14
11/21/17
17:14
Hot Stocks
Salesforce: Amazon.com continues to be key partner in International expansion »

Says International…

CRM

Salesforce

$108.80

1.43 (1.33%)

AMZN

Amazon.com

$1,139.49

13.18 (1.17%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Nov

  • 27

    Nov

  • 18

    Mar

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.